The FDA approved tenecteplase (TNKase) for adult stroke patients, Genentech announced on Monday. A clot-dissolving tissue plasminogen activator (tPA), tenecteplase is now indicated for acute ischemic ...

Researchers at UT Southwestern Medical Center found that tenecteplase, a newer drug, is just as safe and effective as ...

A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a ...

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according to the manufacturer.Genentech said in a press release that TNKase ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

The study, published March 12 in JAMA Network Open, compared the newly approved tenecteplase in a single quick injection to alteplase, the stroke treatment that has been used for decades and requires ...

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...

Two randomized trials in China find that intra-arterial thrombolysis with urokinase or tenecteplase does not significantly ...

Intra-arterial tenecteplase administered after successful thrombectomy in patients with large vessel occlusion between 4.5 and 24 hours post-onset increases the likelihood of achieving a modified ...